Loading
Medicare pays clinics the drug's average sales price plus 6%, so a dearer drug earns the clinic more; replacing the percentage with a flat handling fee removes the incentive to pick the expensive option.
Under Part B, clinician-administered drugs are reimbursed at the average sales price plus 6% (reduced by sequestration). The add-on scales with price, so two equally effective drugs earn a practice very different margins. A flat per-administration fee, set to cover handling and inventory cost, would make the choice between a biosimilar and its reference product, or between two similar checkpoint inhibitors, financially neutral for the prescriber. MedPAC has recommended variants of this for a decade.
Shares 340B Drug Pricing Program, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares 340B Drug Pricing Program, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value, National Cancer Institute (NIH).
Shares 340B Drug Pricing Program, Biosimilar, Prices and value.
Shares Biosimilar, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Biosimilar, Prices and value.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/